Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FSV05
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,424
Award facts
- Contract value 100% obligated
- $3,424.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,424.46 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector vials. The delivery order, issued on November 12, 2025, with an ultimate completion date of December 4, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was selected as the awardee based on its established performance as a critical supplier within the federal pharmaceutical supply chain and its expertise in distributing a comprehensive range of pharmaceutical products and medical consumables to Department of Defense facilities.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, valued at $499,999,999 with a completion date of December 31, 2036, positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors authorized to supply branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare operations globally. The company's extensive product portfolio, which includes specialty pharmaceuticals and biologics such as Xolair, supports the recurring medical supply needs of military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DB26FSV05?
SPE2DB26FSV05 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DB26FSV05 worth?
The government has obligated $3,424 on SPE2DB26FSV05.
Is contract SPE2DB26FSV05 an order under another contract?
Yes. SPE2DB26FSV05 is a delivery order under SPE2DB22D9367, an indefinite delivery contract.
Was contract SPE2DB26FSV05 competed?
The extent of competition for SPE2DB26FSV05 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award